Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.23
- Piotroski Score 4.00
- Grade Outperform
- Symbol (ARVN)
- Company Arvinas, Inc.
- Price $22.69
- Changes Percentage (4.85%)
- Change $1.05
- Day Low $21.17
- Day High $22.69
- Year High $53.08
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $66.50
- High Stock Price Target $123.00
- Low Stock Price Target $24.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.05
- Trailing P/E Ratio -4.41
- Forward P/E Ratio -4.41
- P/E Growth -4.41
- Net Income $-367,300,000
Income Statement
Quarterly
Annual
Latest News of ARVN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago
Arvinas, Inc. (NASDAQ: ARVN) has seen a significant 74% drop in share price over three years. Despite strong revenue growth, the lack of profitability raises concerns about the company's future perfor...
By Yahoo! Finance | 2 months ago -
Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now
The article discusses the top small-cap healthcare stocks to invest in, focusing on Arvinas, Inc. (NASDAQ:ARVN), a biopharmaceutical company specializing in protein degradation therapeutics....
By Yahoo! Finance | 2 months ago -
ARVN Stock Price | Arvinas Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
Arvinas, Inc. is a biopharmaceutical company focusing on developing therapies to degrade disease-causing proteins. Their product candidates include ARV-110, ARV-471, and ARV-766 targeting specific pro...
By MarketWatch | 3 months ago
